Here's your latest roundup of Houston startup and innovation news you may have missed. Photo via Getty Images

We're on the other side of the hill that is Houston's summer, but the Bayou City's still hot — especially in terms of innovation news, and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, a Houston venture capital fund has made its latest investment, Houston startups share big updates, and more.

Rivalry Technology rolls out mobile ordering at hot summer spot

You can now order poolside at this Houston-area resort. Image courtesy of Rivalry Tech

Lounging at Margaritaville Lake Resort at Lake Conroe was just made easier by Rivalry Tech, a Houston-based mobile ordering platform company. Rivalry Tech upgraded poolside ordering with its myEATz. According to a news release, customers can now order food and drinks from the 5 o’Clock Somewhere Bar and Lone Palm Bar via a custom QR code system for each lounge chair and table to increase operational efficiency for the Margaritaville Lake Resort staff.

“We wanted to be sure the rollout of the myEATz mobile ordering platform was helpful to the Margaritaville staff, not a hindrance to their existing process. We created custom QR codes and a color coded map to easily identify where the mobile orders are going,” says Charles Willis, COO of Rivalry Tech, in the release.

Rivalry, which provides mobile ordering at numerous sports stadiums and venues with sEATz, expanded into hospitality this year.

“The Rivalry Tech team helped us to seamlessly implement mobile ordering at Margaritaville Lake Resort. They created the marketing materials, established custom QR codes, uploaded mentors and trained our staff onsite. The whole process has been easy and collaborative,” says Amit Sen, director food and beverage for Margaritaville Lake Resort, in the release.

Mercury Fund invests in ReturnLogic's latest round

Mercury has led the latest fundraising round from a SaaS company. Image via Getty Images

Houston-based venture capital firm Mercury led Phillidelphia-based SaaS company ReturnLogic's $8.5 million series A funding round, which also had participation from Revolution’s Rise of the Rest Fund, White Rose Ventures, and Ben Franklin Technology Partners. The fresh funding will help the company double its workforce, accelerate product development, and expand Application Programming Interface capabilities, according to a news release.

Founded by CEO Peter Sobotta, Return Logic's SaaS platform, which can be plugged into existing e-commerce platforms, helps to enhance management of returns and prevent the challenging financial impacts of returns.

“While retailers have largely mastered forward logistics to get products into customers hands, the returns process remains an under-addressed, resource-draining problem that eats away at brands’ profits,” says Blair Garrou, managing director of Mercury, in a news release. “ReturnLogic is something entirely new to this market and uniquely built on Peter Sobotta’s deep operational experience in reverse logistics and supply chain management.

"While serving in the U.S. Navy, Peter specialized in reverse logistics and gained extensive expertise in ecommerce operations," Garrou continues. "With Peter at the helm, ReturnLogic’s innovative API-first returns solution is well-positioned to tackle the ever-growing operational returns problem facing retailers. We are excited to partner with Peter and his team as they continue to solve this massive problem for online retailers.”

Fluence Analytics named a top advanced manufacturing startup

Fluence Analytics was selected as one of 50 startups recognized. Graphic courtesy

Fluence Analytics, an analytics and process control solutions platform for the polymer and biopharmaceutical industries, was named as a Top 50 global advanced manufacturing startup by CB Insights. The Inaugural list breaks down 16 different cohorts, narrowed down from more than 6,000 companies who either submitted an application or were nominated. Fluence Analytics was one of three companies featured in the R&D Optimization category.

"Our team is very excited that our real-time process analytics, optimization and control products for the polymer and biopharma industries are included among such elite startups," says Jay Manouchehri, CEO of Fluence Analytics, in a statement to InnovationMap. "We wish to thank CB Insights for including Fluence Analytics in its inaugural list of the Top 50 global advanced manufacturing startups, as well as our customers and investors for supporting the development and roll-out of our transformative technology solutions."

Fluence Analytics moved to the Houston area from New Orleans last year. The company's tech platform allows for optimization and control products to polymer and biopharmaceutical customers worldwide.

HTX Labs secures $1.7M contract to expand within United States Air Force

HTX Labs' EMPACT product will be further developed to support the Air Force. Image courtesy of HTX Labs

HTX Labs, a Houston-based company that designs extended reality training for military and business purposes, that it has been awarded a $1.7 million Small Business Innovation Research Phase II Tactical Funding Increase with the US Air Force to enhance and operationalize to its product, EMPACT Immersive Learning Platform, in support of training modernization.

“We are very thankful to AFWERX and AFDT for this great opportunity to play an increasingly important role in helping the USAF accelerate training modernization," says Chris Verret, president HTX Labs, in a news release. "This TACFI award shows continued confidence in HTX Labs, with a strong commitment to accelerate usage and adoption of EMPACT.”

HTX Labs will leverage this contract to expand EMPACT's ability to rapidly create and distribute interactive, immersive training, collaborating closely with Advanced Force Development Technologies, per the release.

OpenStax to publish free edition of updated science textbook

OpenStax is growing its access to free online textbooks. Image via openstax.org

OpenStax, a tech initiative from Rice University that uploads free learning resources, has announced it will publish the 10th edition of an organic chemistry textbook by Cornell University professor emeritus John McMurry.

“This is a watershed moment for OpenStax and the open educational resources (OER) movement,” says Richard Baraniuk, founder and director of OpenStax, in a news release. “This publication will quickly provide a free, openly licensed, high-quality resource to hundreds of thousands of students in the U.S. taking organic chemistry, removing what can be a considerable cost and access barrier.”

Usually a big expense for organic chemistry students, McMurry, with the support of publisher Cengage, made the decision to offer the latest edition online as a tribute to his son, Peter McMurry, who died in 2019 after a long struggle with cystic fibrosis.

“If Peter were still alive, I have no doubt that he would want me to work on this 10th edition with a publisher that made the book free to students,” McMurry says in the release. “To make this possible, I am not receiving any payment for this book, and generous supporters have covered not only the production costs but have also made a donation of $500,000 to the Cystic Fibrosis Foundation to help find a cure for this terrible disease.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.